Anavex Life Sciences Corp.
AVXL · NASDAQ
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.83 | 3.41 | -1.12 |
| FCF Yield | -5.14% | -6.50% | -5.32% | -3.05% |
| EV / EBITDA | 0.00 | 64.60 | -6.66 | -12.65 |
| Quality | ||||
| ROIC | 0.00% | -43.97% | -38.40% | -1.39% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.84 | 0.72 | 0.58 | 0.51 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -26.72% | -10.89% | -14.63% | 20.23% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -24.97 | 2.71 | 2.93 |
| Interest Coverage | 0.00 | 0.00 | -57.84 | -53.84 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |